OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine
暂无分享,去创建一个
H. Diener | R. Lipton | S. Silberstein | D. Dodick | S. Aurora | C. Turkel | B. Grosberg | S.D. Silberstein | F. Freitag | D.W. Dodick | F. Freitag | R.B. Lipton | S.F. Varon | B. Grosberg | P.J. McAllister | S.K. Aurora | H.C. Diener | R.E. DeGryse | M.E. Nolan | C.C. Turkel | P. McAllister | S. Varon | Hans-Christoph Diener | C. Turkel | R. Degryse | M. E. Nolan | Marissa E. Nolan
[1] B. Gandek,et al. Measuring the Functional Status and Well‐Being of Patients with Migraine Headache , 1994, Headache.
[2] R. Lipton,et al. Economic Burden of Transformed Migraine: Results From the American Migraine Prevalence and Prevention (AMPP) Study , 2009, Headache.
[3] R. Hays,et al. Approaches and Recommendations for Estimating Minimally Important Differences for Health-Related Quality of Life Measures , 2005, COPD.
[4] A. Dowson,et al. A six-item short-form survey for measuring headache impact: The HIT-6™ , 2003, Quality of Life Research.
[5] R. Lipton,et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: Results from the International Burden of Migraine Study (IBMS) , 2011, Cephalalgia : an international journal of headache.
[6] M. Rupnow,et al. Validation of the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ v. 2.1) for patients undergoing prophylactic migraine treatment , 2007, Quality of Life Research.
[7] S. Aurora. Botulinum toxin type A for the treatment of migraine , 2006, Expert opinion on pharmacotherapy.
[8] H. Diener,et al. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial , 2010, Cephalalgia : an international journal of headache.
[9] S. Silberstein,et al. Headache Prophylaxis With BoNTA: Patient Characteristics , 2010, Headache.
[10] H. Diener,et al. The Importance of Placebo in Headache Research , 2008, Cephalalgia : an international journal of headache.
[11] J. Bjorner,et al. The Short-Form Headache Impact Test (HIT-6) was psychometrically equivalent in nine languages. , 2004, Journal of clinical epidemiology.
[12] J. Olesen,et al. New Appendix Criteria Open for a Broader Concept of Chronic Migraine , 2006, Cephalalgia : an international journal of headache.
[13] Min Yang,et al. Validation of the Headache Impact Test (HIT-6™) across episodic and chronic migraine , 2011, Cephalalgia : an international journal of headache.
[14] W. Young,et al. Quality‐of‐Life Differences Between Patients With Episodic and Transformed Migraine , 2001, Headache.
[15] S. Silberstein,et al. The Impact of Topiramate on Health‐Related Quality of Life Indicators in Chronic Migraine , 2007, Headache.
[16] J. Kaufman,et al. Four methods of estimating the minimal important difference score were compared to establish a clinically significant change in Headache Impact Test. , 2006, Journal of clinical epidemiology.
[17] H. Diener,et al. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial , 2010, Cephalalgia : an international journal of headache.
[18] M. Marmura,et al. New therapeutic developments in chronic migraine , 2010, Current opinion in neurology.
[19] M. Rupnow,et al. Minimal Important Differences in the Migraine-Specific Quality of Life Questionnaire (MSQ) Version 2.1 , 2009, Cephalalgia : an international journal of headache.
[20] R. Rendas-Baum,et al. PND26 VALIDATING USE OF THE MIGRAINE-SPECIFIC QUALITY OF LIFE QUESTIONNAIRE VERSION 2.1 (MSQ) ACROSS MIGRAINE DISORDERS , 2010 .
[21] D. Dodick,et al. Chronic Daily Headache , 2006 .
[22] R. Lipton,et al. Employment and Work Impact of Chronic Migraine and Episodic Migraine , 2010, Journal of occupational and environmental medicine.
[23] R. Lipton,et al. Assessment of Migraine Disability Using the Migraine Disability Assessment (MIDAS) Questionnaire: A Comparison of Chronic Migraine With Episodic Migraine , 2003, Headache.
[24] T. Redman. The Impact of , 1998 .
[25] Jes Olesen,et al. The International Classification of Headache Disorders: 2nd edition. , 2004, Cephalalgia : an international journal of headache.
[26] S. Davis,et al. MSQ: Migraine-Specific Quality-of-Life Questionnaire. Further investigation of the factor structure. , 1998, PharmacoEconomics.
[27] R. Lipton,et al. Guidelines for Controlled Trials of Prophylactic Treatment of Chronic Migraine in Adults , 2008, Cephalalgia : an international journal of headache.
[28] M. Brin,et al. OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double‐Blind, Randomized, Placebo‐Controlled Phases of the PREEMPT Clinical Program , 2010, Headache.
[29] D. Dodick. Clinical practice. Chronic daily headache. , 2006, The New England journal of medicine.
[30] R. Lipton,et al. Chronic migraine in the population , 2008, Neurology.
[31] J. Farrar,et al. Interpreting the clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendations , 2009, PAIN.
[32] S. Silberstein,et al. The Headache Management Trial: A Randomized Study of Coordinated Care , 2008, Headache.
[33] J. Dartigues,et al. Impact of Headache on Quality of Life in a General Population Survey in France (GRIM2000 Study) , 2004, Headache.
[34] R. Lipton,et al. Global prevalence of chronic migraine: A systematic review , 2010, Cephalalgia : an international journal of headache.
[35] S. Silberstein,et al. Method of Injection of OnabotulinumtoxinA for Chronic Migraine: A Safe, Well‐Tolerated, and Effective Treatment Paradigm Based on the PREEMPT Clinical Program , 2010, Headache.